This is small -- but worthy of its own post, I believe. Two national columnists, this week, ran these headlines, about the proposed Sch-Merck transaction (the second refers also to the J&J Remicade/Simponi potential for reversion of non-US distribution rights) -- do click the embedded links, in each, to read the whole articles. They are very worthy reads:
. . . ."Schering and Merck: A Match Made in Purgatory"
-- Brian Orelli, The Motley Fool. . . .
. . . ."Who is the Most Desperate in This Bizarre Love Triangle?"
-- Jim Edwards, BNET Pharma. . . .
